Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies(NIHR Leicester Biomedical Research Centre), John B. Buse(Unknown), Stefano Del Prato(University of Pisa), Chantal Mathieu(KU Leuven), Geltrude Mingrone(University of the Sacred Heart), Tsvetalina Tankova(Medical University of Sofia), Billy S. Collins, Nisa M. Maruthur(Johns Hopkins University), Robert A. Gabbay(Harvard University), Peter Rossing(Steno Diabetes Centers), Sylvia E. Rosas(Joslin Diabetes Center), Vanita R. Aroda(Brigham and Women's Hospital), Jennifer Green(Duke University), Απόστολος Τσάπας(Aristotle University of Thessaloniki)
Cited by 986
Related Papers
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2018|3.5k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|2.4k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k